Drug Profile
Olanzapine intranasal - Impel Pharmaceuticals
Alternative Names: INP 105; POD™ olanzapineLatest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Oxazepines; Small molecules; Thiazepines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Aggression; Agitation
Most Recent Events
- 26 Sep 2023 Impel Pharmaceuticals terminates phase-II CALM 201 trial in Agitation (In adolescents) in USA (Intranasal), due to business reason (NCT05163717)
- 22 Feb 2023 Discontinued - Phase-I for Aggression (Intranasal)
- 22 Feb 2023 Discontinued - Phase-I for Agitation (In volunteers) in Australia (Intranasal)